Home › Blog › Weight Loss › Mounjaro NHS

Mounjaro NHS 2026: Who Qualifies, Cohort 2 Criteria, Waiting Times & Private Options

NHS access to Mounjaro (tirzepatide) for weight management in England runs on two tracks. In specialist weight management services, the full NICE TA1026 eligibility criteria apply — a BMI of at least 35 with at least one weight-related comorbidity. In primary care, access is phased through prioritised cohorts, and Cohort II activated on 23 June 2026 covering BMI 35–39.9 with at least four qualifying comorbidities. That distinction is the single most important thing on this page, and it is the thing most coverage gets wrong. This guide explains both routes, who qualifies for each, and what the options are if neither currently fits.

NHS Mounjaro at a glance

The distinction that changes everything

Almost every misunderstanding about NHS Mounjaro comes from treating “the NHS criteria” as a single thing. There are two routes with different criteria, and knowing which one you are asking about changes the answer entirely.

Route 1: specialist weight management services

Here the full NICE TA1026 criteria apply: a BMI of at least 35, plus at least one weight-related comorbidity, with the usual 2.5 kg/m² reduction for the specified ethnic backgrounds. ICBs have been required to fund this for anyone meeting those criteria since 24 March 2025, where a prescribing clinician considers treatment appropriate.

The important caveat is that ICBs have the option to align specialist service access with the same cohorting approach used in primary care, in order to prioritise resources. So the criteria are broader on paper, but local prioritisation and service capacity determine what happens in practice.

Route 2: primary care

Here access is phased through prioritised cohorts, reflecting available capacity in a new setting of care. This is where the four-comorbidity requirement comes from, and it is considerably narrower than TA1026 itself.

Why this matters to you

If you have a BMI of 36 and one comorbidity, you fall outside primary care Cohort II — but you are within the full TA1026 criteria that apply in specialist weight management services. A great many people who have been told “you don’t meet the NHS criteria” have only been told about the primary care cohorts.

And a third gate: the licence

Wider still is the marketing authorisation, which covers BMI 30 or above, or 27 to 29.9 with at least one weight-related condition. That is what private prescribing works to. Being licence-eligible does not mean being TA1026-eligible, and being TA1026-eligible does not mean being cohort-eligible.

Cohort II: who qualifies in primary care now

Primary care Cohort II went live on 23 June 2026. To be eligible for the primary care route you need both of the following.

Cohort I has not been withdrawn. Funding variation Year 2 covers Cohorts I and II together, so adults with a BMI of 40 or above (37.5 or above adjusted) and four qualifying comorbidities remain eligible, as they have been since 23 June 2025.

The five qualifying comorbidities — and their exact definitions

For the primary care cohorts you need at least four of these five. NHS England defines each one specifically, and the definitions are stricter than most summaries suggest. A condition you have but which does not meet the definition below will not count.

If you have symptoms suggestive of an undiagnosed condition — loud snoring with witnessed pauses in breathing and daytime sleepiness, for instance — that is worth raising in its own right. Investigating a genuine symptom is good medicine. Chasing a diagnosis in order to qualify for something is not, and your GP will recognise the difference.

The ethnic BMI adjustment

BMI thresholds are reduced by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean family backgrounds. This is because cardiometabolic risk occurs at lower BMI in these populations.

The adjustment applies to the BMI threshold only. The four-condition requirement is unchanged.

The QOF indicators: what changed in April 2026

From April 2026, the QOF 2026/27 update to the GP contract introduced two obesity indicators. They are designed to support practices to consistently identify adults living with obesity and enable equitable access to weight management support — including behavioural interventions and treatment options where appropriate, following shared decision-making with the patient.

Both indicators align with the NICE quality standard on the prevention, behavioural management, assessment and treatment of overweight, obesity and central adiposity in adults.

What the QOF update did not change

It changed the framework supporting identification and consideration, not the eligibility criteria. The BMI thresholds and comorbidity requirements are set by the NICE funding variation, not by QOF.

How local access is organised — and what to ask

NHS England requires every ICB to have a defined approach to accessing weight management pharmacotherapy, ensuring patients meet the clinical criteria before treatment is considered, accessed via the most appropriate care setting. What varies is the delivery model, not whether an approach exists at all.

NHS England worked with ICBs to set out four indicative implementation models for primary care:

• Community or local-based delivery model
• General practice delivery model
• Specialist weight management services community outreach model
• Specialist weight management services community and general practice shared-care model

These are indicative and intended to inform local planning. ICBs have flexibility to choose the model or models that suit their population, with the aim of growing and scaling them over the initial three-year period.

What this means for you practically: the route into treatment in your area may or may not run through your own GP practice. It might be a community service, a specialist outreach clinic, or a shared-care arrangement. So the useful question is not “will my GP prescribe this” but “what is the local pathway”.

Cohort III and what comes after

The published cohorting approach covers the first three years of implementation, from 2025 to 2028. Access widens sequentially from Cohort I through to Cohort III.

Note what Cohort III does: it relaxes the comorbidity count for people at the highest BMI, rather than lowering the BMI threshold further. Someone with a BMI of 41 and three comorbidities becomes eligible; someone with a BMI of 36 and three does not.

The rollout so far

How to access NHS Mounjaro

Step 1: work out which route you might fit

If you have a BMI of 35 or above and one weight-related comorbidity, you meet the full TA1026 criteria that apply in specialist weight management services. If you also have four qualifying comorbidities, you additionally meet the current primary care cohort criteria. Those are different conversations.

Step 2: don’t request it by name

NHS England has asked patients not to contact their GP to request Mounjaro by name. Eligible patients are largely identified from GP records, and local arrangements manage access. Ringing to ask for a named drug is the approach least likely to work.

Step 3: raise your weight and your health conditions

What does work is a conversation about your weight, the conditions it is affecting, and what weight management support is available locally. That is a legitimate reason for an appointment and puts the question in a frame your GP can act on.

Step 4: ask about both routes

Ask what the local pathway is for weight management pharmacotherapy, and separately whether you are eligible for referral to specialist weight management services. A great many people only ever ask about the first.

Step 5: expect a thorough assessment

Initial assessment should be carried out by an appropriately trained healthcare professional and covers, as a minimum, BMI and comorbidity assessment, medical history and concomitant medication, suitability including contraindications, cautions and psychological assessment, and a review of polypharmacy. Prescribers are also asked to consider overall wellbeing carefully where eating disorders, body dysmorphia or mental health are factors.

Talking to your GP: what actually helps

What to say

“I’d like to talk about my weight and the health conditions it’s affecting. I have [list them]. Could we discuss what weight management support and treatment options are available here, and whether I might be eligible?”

What to bring

• An accurate current height and weight — weigh yourself rather than estimating
• A list of your diagnosed conditions, with approximate dates
• Whether you are on treatment for blood pressure or lipids, since the definitions depend on it
• Recent blood results — HbA1c, lipid profile — if you have access to them
• Your current medicines list

Five questions worth asking

• “What is the local pathway for weight management medication here — practice, community service, or specialist service?”
• “Am I eligible for referral to specialist weight management services under the full TA1026 criteria?”
• “Based on my record, how many of the five qualifying comorbidities do I meet the definitions for?”
• “Is my hypertension recorded as treated, and do my lipid results meet the dyslipidaemia definition?”
• “Is there anything in my record that should be investigated in its own right?”

If you’re told you don’t qualify

This is the outcome for a lot of people who ask, so it is worth knowing what it does and does not mean.

Ask which route you were assessed against. “Don’t qualify” often means the primary care cohorts specifically. The full TA1026 criteria in specialist services are wider, and it is a separate question.

It is usually the comorbidity count or definitions, not the BMI. Ask which comorbidities are recorded and which fall short of the definition. Sometimes a condition you are treated for is not coded in the way the criteria require.

It may reflect local capacity rather than your clinical position. ICBs may prioritise specialist service access using the cohorting approach. That is a resourcing decision, not a judgement about you.

It does not mean nothing else can be done. Ask about semaglutide under NICE TA875, the type 2 diabetes route if that applies, the cardiovascular route if you have established CVD, and what behavioural and dietetic support is commissioned locally. NHS pharmacotherapy is one option among several.

And the licensed criteria are wider than either NHS route. A great many people outside the NHS cohorts are squarely within the marketing authorisation.

Waiting times: what to expect

Where the specialist weight management route is the one available to you, waiting time is the main practical barrier. It varies substantially between and within Integrated Care Board areas.

Nationally, waits of a year or more are common, and in areas with less commissioned capacity they can be considerably longer. Some ICBs that invested early in community weight management services move faster than others.

Why your postcode matters as much as your BMI

NHS England sets the national framework. Implementation is devolved to Integrated Care Boards, each of which decides:

• Which weight management services to commission, and at what capacity
• How actively to support the QOF pathway with local practices
• The pace of implementing each cohort within their area
• Whether to commission community-based services alongside specialist ones

The result is real geographic variation in how quickly an eligible patient is actually seen. This is not a failure of any individual ICB so much as the predictable consequence of devolved commissioning against a large budget impact.

How to find your area’s position

• Ask your GP practice directly — they will know the local arrangement
• Check your ICB’s website, where most publish medicines commissioning policies
• Contact your ICB’s patient services team

The type 2 diabetes route: a different pathway

Tirzepatide holds a separate UK licence for type 2 diabetes, appraised by NICE under a different technology appraisal (TA924) with different eligibility criteria from the weight management route.

This matters because for some people it is a more accessible route. QOF 2026/27 indicators recognise GLP-1 and dual GIP/GLP-1 agonists in type 2 diabetes management, which means tirzepatide can sit within standard diabetes care at GP level rather than being solely a specialist weight management medicine.

The NHS Wegovy route

For people who do not meet the Mounjaro cohort criteria, semaglutide (Wegovy) is a separate NHS route with different criteria under NICE TA875, accessed through specialist weight management services.

The single-condition requirement makes TA875 more accessible on paper for a lot of people who fall short of Mounjaro’s four-condition gate. The trade-off is that it runs through specialist services, where capacity is the limiting factor. It is worth asking your GP about both routes rather than only the one you have read about.

The cardiovascular route — new in 2026

If you have established cardiovascular disease, there is a third NHS route that did not exist a year ago and that many people are not aware of.

NICE TA1152, published 7 May 2026, recommends semaglutide for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of at least 27. Established cardiovascular disease here means a previous heart attack, a previous ischaemic or haemorrhagic stroke, or symptomatic peripheral arterial disease meeting a specific definition.

Two features make this route worth knowing about. The BMI threshold is 27, considerably lower than either weight management route. And type 2 diabetes does not exclude you — NICE specifically concluded that this population should not be excluded, despite the underlying trial having excluded people with diabetes.

See our Wegovy cardiovascular NHS guide for the full criteria. If you have had a heart attack or stroke, this is worth raising at your next secondary prevention review.

Scotland, Wales and Northern Ireland

Health is devolved, so the cohort structure described above is the NHS England arrangement. The other three nations set their own.

What NHS treatment actually involves

Wraparound care is not optional in either setting. NICE TA1026 effectively mandates it alongside prescribing for all patients receiving tirzepatide, regardless of care setting. Every patient must be provided with support incorporating nutritional and dietetic advice as a minimum, plus access to behavioural change components, as a mandatory requirement to access treatment.

In specialist weight management services

Where treatment is prescribed through a multidisciplinary team offering a combination of nutritional, psychological and medical intervention based on individual need, further wraparound provision is not required — the service already provides it.

In primary care

Additional wraparound care must be provided. ICBs can either use the centrally funded NHS England wraparound service or commission their own, which must incorporate nutritional and dietetic advice, physical activity guidance and behavioural change components over a minimum of nine months from the point of prescribing initiation.

Primary care management is also more structured than many people expect. NHS England guidance specifies monthly face-to-face appointments with a suitably trained healthcare professional during the titration phase, with structured medication reviews for at least the first 12 months of prescribing. Reviews should take a holistic approach — weight and BMI, comorbidity indicators, consideration of deprescribing, and potential adverse effects including psychological impacts.

Continuation of NHS Mounjaro

This is widely misreported, so it is worth stating precisely.

Unlike other NICE-recommended weight management medicines, which currently have a maximum prescription duration of two years, tirzepatide for the management of obesity does not have a set stopping rule or maximum treatment period. Indefinite prescribing is permitted where it remains clinically appropriate.

The decision to continue short or long-term prescribing is made case by case by an appropriately trained healthcare professional in consultation with the patient, weighing clinical benefits and risks.

NHS England advises that if at least 5% of initial body weight has not been lost after six months at the highest tolerated dose, the clinician should reassess whether continuing treatment remains appropriate and consider alternative therapies where clinical benefit is not being observed.

Prescription charges and exemptions

In England, NHS prescriptions carry the standard charge unless you are exempt. Each pen counts as one prescription item. In Scotland, Wales and Northern Ireland, prescriptions are free.

Common exemption categories in England

• Aged 60 or over
• Under 16, or under 19 and in full-time education
• Holding a valid medical exemption certificate — which includes diabetes treated with medication, and hypothyroidism requiring replacement therapy
• Receiving certain benefits
• Holding a valid maternity exemption certificate

Prescription prepayment certificates

If you pay for prescriptions and take several regular medicines, a prescription prepayment certificate caps your total charges over three or twelve months. For anyone on multiple regular items it usually saves money. Current charges and PPC prices are published on the NHS website.

NHS versus private: an honest comparison

The active medicine and licensed UK product are the same whether supplied privately or through the NHS. What differs is who you see, how long you wait, what it costs and what support surrounds it. If you are eligible for an NHS route and can wait, that route is substantially cheaper and comes with mandated wraparound care. If the primary care cohorts do not fit, ask about specialist weight management services, about semaglutide under TA875, and about the diabetes and cardiovascular routes before concluding the NHS has nothing to offer. Where none of those applies, private treatment works to the wider licensed criteria.

Starting private while waiting for an NHS place

This comes up constantly, so it is worth addressing directly and without overselling it.

Starting privately does not remove you from an NHS waiting list. You can be waiting for a specialist weight management appointment and receiving private treatment at the same time.

Tell your GP. This is not optional. Tirzepatide affects blood glucose and blood pressure, interacts with other medicines, and matters for any surgery or procedure. Your GP needs it in your record, and your specialist service will need to know at assessment.

Transitioning is a clinical decision, not an administrative one. If an NHS place becomes available, the team will assess where you are — your current dose, tolerance and response — and decide how to proceed. Your private provider can supply a treatment summary.

Think about cost before you start, not after. The most common bad outcome here is starting privately, finding the cost unsustainable at maintenance doses, stopping abruptly, and regaining weight before the NHS place arrives. Starting and stopping repeatedly is worse than a planned wait. Plan against the maintenance dose price, not the starting dose price.

Full cost comparison over twelve months

Slinic prices are fixed 2026 prices, last verified 4 August 2026. No subscription, no minimum term. All supply subject to clinical approval.

The NHS route is dramatically cheaper for anyone who can access it. That saving is only real if you are actually eligible and your local pathway is open — which is precisely the question this guide exists to help you answer.

Worked examples

These illustrate how the criteria apply. They are not individual advice — only a clinician with access to your records can tell you where you stand.

Common misunderstandings

“The NHS criteria are BMI 35 with four conditions.” That is the primary care cohort. In specialist weight management services the full TA1026 criteria apply — BMI 35 with one comorbidity.

“Cohort II means BMI 35 is enough.” Not for the primary care route. The four-comorbidity requirement did not change.

“I have high blood pressure, so that’s one condition.” Only if you require blood pressure lowering therapy. The definitions are specific and stricter than most summaries suggest.

“NICE approved it, so the NHS has to give it to me.” NICE recommended it and granted a funding variation permitting phased implementation in primary care. Specialist services are funded for the full criteria; primary care is phased.

“My GP is refusing because they’re being difficult.” Far more often it is the comorbidity count, a definition not met, or the local delivery model routing access somewhere other than the practice.

“I’ll ask for it by name and push.” NHS England has specifically asked patients not to do this.

“Prediabetes counts.” Not for this purpose. The listed comorbidity is established type 2 diabetes.

“NHS treatment stops after two years.” That applies to some other weight management medicines. Tirzepatide has no maximum treatment period and may be prescribed indefinitely where clinically appropriate.

“If I don’t lose 5% they’ll stop it automatically.” The 5% at six months figure is a reassessment trigger at the highest tolerated dose, not an automatic stopping rule.

“Primary care means no support.” Wraparound care is mandatory in both settings, with monthly appointments during titration and structured medication reviews for at least the first 12 months in primary care.

“Private and NHS are different medicines.” The active medicine and licensed UK product are the same. What differs is the pathway, the cost and the support.

“If I start privately I lose my NHS place.” You do not.

Frequently asked questions

Summary

NHS access to Mounjaro in England runs on two tracks with different criteria. Specialist weight management services are funded for the full NICE TA1026 population — BMI 35 or above with at least one weight-related comorbidity. Primary care access is phased through prioritised cohorts, and Cohort II, live since 23 June 2026, requires BMI 35–39.9 with four qualifying comorbidities.

If you have been told you do not meet “the NHS criteria”, it is worth establishing which criteria you were assessed against. A BMI of 36 with one comorbidity falls outside the primary care cohorts but sits within TA1026, and referral to specialist services is a separate question. Beyond that, semaglutide under TA875, the type 2 diabetes route under TA924 and the cardiovascular route under TA1152 are all worth asking about before concluding the NHS has nothing to offer.

Where none of those fits, the licensed criteria — BMI 30 or above, or 27 to 29.9 with a weight-related condition — are wider than any NHS route, and private treatment works to them.

Mounjaro is a prescription-only medicine and a Black Triangle medicine subject to additional safety monitoring. This guide is general information about commissioning arrangements and does not replace advice from your GP or an individual clinical assessment.

Related guides and treatment pages

References

1. NHS England — interim commissioning guidance, implementation of NICE TA1026 (tirzepatide).
2. NICE TA1026 — Tirzepatide for managing overweight and obesity.
3. NICE TA875 — Semaglutide for managing overweight and obesity.
4. NICE TA924 — Tirzepatide for treating type 2 diabetes.
5. NICE TA1152 — Semaglutide for reducing the risk of major adverse cardiovascular events.
6. NICE NG246 — Overweight and obesity management.
7. NHS England — QOF 2026/27 changes, including obesity indicators OB004 and OB005.
8. NHS England — Tirzepatide in primary care for weight management: information on wraparound care.
9. NICE QS212 — Overweight, obesity and central adiposity in adults quality standard.
10. NHS Cheshire and Merseyside ICB — tirzepatide prescribing statement.
11. BMJ. Freedom of Information investigation into NHS integrated care board tirzepatide prescribing, 2025.
12. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
13. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Investigators. Tirzepatide as compared with semaglutide. N Engl J Med. 2025. doi:10.1056/NEJMoa2416394
14. NHS — prescription charges, exemptions and prepayment certificates.
15. General Pharmaceutical Council — register of pharmacies and pharmacy professionals.